The FDA-Approved Breast Cancer HER2 Evaluation Kit (HercepTest; Dako) May Miss Some HER2-Positive Breast Cancers
Author:
Affiliation:
1. Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA
2. Department of Pathology, University of Utah, Salt Lake City
Publisher
Oxford University Press (OUP)
Subject
General Medicine
Link
http://academic.oup.com/ajcp/article-pdf/151/5/504/28264964/aqy171.pdf
Reference39 articles.
1. HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies;English;Mol Diagn Ther.,2013
2. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review;Dawood;J Clin Oncol.,2010
3. ERBB2 (HER2) testing in breast cancer;Hilal;JAMA.,2016
4. New developments in breast cancer and their impact on daily practice in pathology;Li;Arch Pathol Lab Med.,2017
5. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease;Cobleigh;J Clin Oncol.,1999
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Correlation of HER2 Protein Level With mRNA Level Quantified by RNAscope in Breast Cancer;Modern Pathology;2024-02
2. Atypical Co-amplification with Co-localization of HER2 Gene in Breast Cancer: Combined IHC/FISH Approach as per ASCO/CAP 2018 Guidelines for Targeted Therapy Eligibility;Indian Journal of Surgical Oncology;2023-10-13
3. Low interobserver agreement among subspecialised breast pathologists in evaluating HER2-low breast cancer;Journal of Clinical Pathology;2023-09-15
4. HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer;Pathology - Research and Practice;2020-11
5. Quantitative Impact of the 2018 American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) Practice Guideline Update on Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: A Systematic Analysis;Archives of Pathology & Laboratory Medicine;2020-10-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3